



Onpattro in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

RARE DISEASE · HATTR POLYNEUROPATHY

The clinical situation

Onpattro (patisiran) is an intravenous lipid-nanoparticle-delivered siRNA targeting hepatic TTR mRNA, FDA-approved for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Manufactured by Alnylam. Administration is a weight-based IV infusion once every three weeks, with standard premedication (corticosteroid, paracetamol, H1 and H2 blockers) to prevent infusion-related reactions. Pre-treatment workup covers TTR genotype confirmation, vitamin A supplementation counselling, and baseline neurological assessment per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist documents hATTR polyneuropathy diagnosis, staging, TTR genotype, and Onpattro rationale.
- 2 Baseline workup.** Vitamin A supplementation counselling, neurologic baseline, premedication plan, infusion-site arrangements per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, q3-week dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the infusion vials; first infusion scheduled at the treating centre with premedication.

Indicative economics

Reference US cash-pay range: USD 440,000–480,000 per year of Onpattro (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Alnylam authorised distribution.

Documentation. Physician kit tailored to SFDA review, with TTR-genotype and IRR-prevention premedication annex.

Logistics. Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through every three-week infusion cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Onpattro × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/onpattro-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team